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Previously, fluorodeoxy glucose conjugated magnetite nanoparticles (FDG-mNPs) injected
into cancer cells in conjunction with the application of magnetic hyperthermia have shown
promise in new FDG-mNPs applications. The aim of this study was to determine potential
toxic or unwanted effects involving both tumour cells and normal tissue in other organs
when FDG-mNPs are administered intravenously or intratumourally in mice.
Materials and methods
FDG-mNPs were synthesized. A group of six prostate-tumour bearing mice were injected
with 23.42 mg/ml FDG-mNPs (intravenous injection, n = 3; intratumoural injection into the
prostate tumour, n = 3). Mice were euthanized and histological sampling of tissue was con-
ducted for the prostate tumour, as well as for lungs, lymph nodes, liver, kidneys, spleen, and
brain, at 1 hour (n = 2) and 7 days (n = 4) post-injection. A second group of two normal (non-
cancerous) mice received the same injection intravenously into the tail vein and were eutha-
nised at 3 and 6 months post-injection, respectively, to investigate if FDG-mNPs remained
in organs at those time points.
Results
In prostate-tumour bearing mice, FDG-mNPs concentrated in the prostate tumour, while rel-
atively small amounts were found in the organs of other tissues, particularly the spleen and
the liver; FDG-mNP concentrations decreased over time in all tissues. In normal mice, no
detrimental effects were found in either mouse at 3 or 6 months.
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Conclusion
Intravenous or intratumoural FDG-mNPs can be safely administered for effective cancer
cell destruction. Further research on the clinical utility of FDG-mNPs will be conducted by
applying hyperthermia in conjunction with FDG-mNPs in mice.
Introduction
The global cancer burden is growing and cancer now causes more deaths than all coronary
heart disease or all stroke. In 2012 there were 14.1 million newly diagnosed cancer cases (exc-
luding non-melanoma skin cancer) worldwide with 8.2 million cancer-related deaths [1]. In
spite of many years of research at high financial cost, a definitive treatment or cure for cancer
presently remains beyond our reach. Although treatments have been developed for cancer,
e.g., radiotherapy and chemotherapy, these are not without their problems and patients con-
tinue to suffer from detrimental side effects. Many of these side effects arise on account of the
highly toxic nature of the chemotherapeutic agents used in the course of the cancer treatment.
It has also been established that in the course of time, cancer cells could develop resistance to
chemotherapeutic agents used in the treatment of cancer [2, 3]. Furthermore, some types of
cancer appear to remain incurable with current radiotherapy and chemotherapy approaches
[4]. Clearly, there is scope and potential for new approaches to the treatment of cancer.
Cancer cells all appear to have one distinguishing feature, namely a higher metabolic rate.
On account of their fast reproductive rate, they consume glucose at a higher rate than normal
cells. This phenomenon is known as the Warburg effect. Cancer cells have a higher rate of glu-
cose uptake with respect to normal cells via the mechanism of glycolysis, which results in the
production of adenosine triphosphate through the process of oxidative phosphorylation. This
effect was lately demonstrated in many cancer types including neuroblastoma [5].
Previous studies including experimental kinds have involved the investigation of the effi-
cacy of magnetic nanoparticles (mNPs) used in conjunction with chemotherapeutic drugs [6,
7]; several have also studied the effect of this approach on cancer destruction when hyperther-
mia is applied, showing higher efficacy depending on the temperature and duration of heating
[8]. This phenomenon is known as magnetic fluid hyperthermia, whereby the sensitisation of
the cancer cells prior to radiotherapy may increase cancer destruction [9–11]. These previous
studies frequently involved the use of iron oxide containing mNPs on account of their biocom-
patibility and low toxicity properties [9–13]. More recent studies have involved the application
of radiofrequency (RF) fields to magnetic nanoparticles that are bound on membrane recep-
tors. RF fields have been associated with dissipation of heat via mNPs, facilitating the destruc-
tion of tumour cells. The results indicate that cellular signalling mechanisms are involved in
cell apoptosis when the temperature of the cancer cell reaches 42˚C [14, 15].
In one of our previous in vitro studies [12], we synthesized fludeoxyglucose (FDG) conjugated
with iron oxide particles specifically as a Positron Emission Tomography-Magnetic Resonance
Imaging (PET-MRI) hybrid compound for potential multimodality medical applications. MCF 7
human breast cancer cells in this study had a higher metabolic rate than normal cells; as such they
were able to readily take up the glucose analogue present in our FDG-mNPs which produced
apoptotic effects on the cancer cells. Recently, another in vitro pilot study we conducted using a
neuroblastoma cell line showed that when FDG-mNPs were injected into these cancer cells and
when magnetic hyperthermia was applied, 89% of the cancer cells were destroyed [14, 16]. Safe
frequencies of hyperthermia for use in human tissues have been long established [5, 17, 18]. Thus,
the present study is an in vivo investigation aimed at discovering if there are potentially any toxic
FDG-mNP in cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0202482 August 20, 2018 2 / 15
Division of Vascular & Endovascular Surgery
Department of Cardiac, Thoracic & Vascular
Surgery National University Heart Centre,
Singapore 1E Kent Ridge Road NUHS Tower Block,
Level 9, Singapore 119228.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: FDG, fludeoxyglucose; FOV, field of
view; H&E, Haemotoxylin and Eosin; ICG,
indocyanine green; ID, inner diameter; mNPs,
magnetic nanoparticles; MRI, Magnetic Resonance
Imaging; MGE, Multiple Gradient Echo; PBS,
phosphate buffer saline; PET, Positron Emission
Tomography; RF, radiofrequency; ROI, region of
interest; TE, echo time; TR, repetition time.
or unwanted effects involving both the tumour cells and other organs in mice when FDG-mNPs
are injected intravenously or intratumourally, without the application of hyperthermia.
Materials and methods
Synthesis of mNPs
Synthesis of mNPs was performed as previously described [12] and chemical structure is shown
in Fig 1. Briefly, 2 M FeCl3 (Fluka, Istanbul, Turkey) was combined with 80 mM Na2SO3 (Merck)
prior to the addition of 25% NH3 solution (Merck) under nitrogen gas. After 30 minutes heating
at 70 oC, the particles were washed with a water–ethanol (2:1) mixture and re-suspended in 80%
ethanol. The particles were mixed with tetraethyl orthosilicate for 12 hours at 40 oC and washed
with methanol prior to incubation with (3-aminopropyl) triethoxysilane (APTES, Sigma, USA)
12 hours at 60 oC with rapid stirring.
Separately, solutions of mannose triflate (Fluka, Istanbul, Turkey) and cysteamine (2-aminoe-
tanethiol; Sigma, Istanbul, Turkey) were prepared in water, mixed heated for 1 hour at 90 oC,
precipitated and dried overnight prior to dissolving in dimethyl formamide (Merck). Next, solu-
tions of Kryptofix (Merck), K2CO3 (Fluka, Istanbul, Turkey) dimethyl formamide (Merkc) and
NaF (Merck) were added to 1 ml of the prepared mannose triflate-cysteamine and heated for 20
minutes at 90 oC. The product was purified by sequential passing through a Dowex 50 cation
exchange resin column (Sigma, USA), Ambersep 900 quaternary ammonium anion exchange
resin (Fluka), Amberlite anion exchange resin (Sigma) and finally a C18 pre-cartridge (Sigma,
USA). The purified NaF substituted mannose triflate-cysteamine was mixed with the mNPs
prior to the addition of N-Hydroxysuccinimide (Merck) and mixing for 2 hours.
For the labelling of mNPs with indocyanine green (ICG), the mNPs were mixed with car-
bonyl diimidazole and N-Hydroxysuccinimide for 15 minutes at room temperature prior to
the addition of ICG solution (Sigma, USA) and a further 15 minutes mixing at room tempera-
ture. Finally, mercaptoethanol (Sigma, USA) was added to the reaction mixture for 2 hours at
room temperature prior to washing and storage in phosphate buffer saline (PBS) at 4 oC. ICG
labelled FDG-mNPs were checked for excitation and emission spectra at 780 nm 820 nm
respectively and eluted in 60% acetonitrile (in distilled water).
In vivo analysis of ICG-conjugated FDG-mNP tissue distribution
All mice and experimental procedures were conducted using protocols approved by and in
accordance with the Weill Cornell Medical Center Institutional Animal Care and Use Com-
mittee and were consistent with the recommendations of the American Veterinary Medical
Association and the National Institutes of Health Guide for the Care and Use of Laboratory
Animals.
Six nude mice (female, weight 20–25 gram) with prostate tumours were used in group 1 by
injection of 1.0 × 106 of PC3 cells into right flank region subcutaneously. Tumours were mea-
sured weekly until volume exceeded>0.5 cm. Animals were anesthetized with gas isoflurane
at 2% concentration mixed with medical grade oxygen. Three mice were injected with FDG-
mNPs into the tail vein, and the remaining three were injected with FDG-mNPs intratumou-
rally directly into the prostate tumours itself, all with a concentration of 23.42 mg/ml (10 mg/
kg body weight). A biodistribution study of each mouse was performed in vivo by 4.7 T MRI
(T2 -4 gradient recalled echo weighted imaging) before and after 1 h and 24 h post injection.
Animals were euthanized by CO2 asphyxiation after scans were completed. Regions of interest
(ROIs) were drawn over the tumour, liver, spleen, right kidney, muscle and lymph node in the
right groin using OsiriX software (Pixmeo SARL, Bernex, Switzerland) and images were nor-
malized to the background (muscle) intensity for each mouse at each imaging time points.
FDG-mNP in cancer
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Fig 1. Chemical structure of FDG-mNP and disruption of cancer cell.
https://doi.org/10.1371/journal.pone.0202482.g001
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Samples were also taken from the left kidney, liver, lung, spleen, muscle and brain. The tumour
and organs (liver, spleen, lungs, liver, brain, muscle, and lymph node) were immersed fixed in
4% Paraformaldehyde for 24 hours, followed by embedding in paraffin. 5 micron sections
were stained for Haemotoxylin and Eosin (H&E) and Prussian blue.
Quantification of iron staining
The slides were digitally scanned with Pannoramic Flash (3DHistech, Hungary) and relevant
tissue areas were exported into tiff format. Quantification of iron staining was performed
using ImageJ/FIJI (NIH, Bethesda, Maryland, USA). A colour deconvolution algorithm was
used, with RGB vectors for the iron positive areas and counterstain/background stain created
from ROIs drawn from example images. Appropriate thresholds were then set for both iron
positive regions as well as the tissue area. All iron positive areas were normalized to the total
tissue area analyzed per region.
In vivo MRI
T2 MRI of the mice was carried out on the 300 MHz Bruker 4.7T Biospec scanners (Bruker
Biospin MRI GmbH, Ettlingen, Germany) equipped with 640 mT/m ID 115 mm gradient
(Resonance Research, Inc., Billerica, MA). RF excitation and acquisition was achieved by a cus-
tom-built quadrature birdcage resonator with an inner diameter (ID) of 32 mm (Stark Con-
trast MRI Coils Research Inc., Erlangen, Germany). The mice were anesthetized with 2%
isoflurane (Baxter Healthcare Corp., Deerfield, IL) gas in oxygen. Animal respiration was
monitored with a small animal physiological monitoring system (SA Instruments, Inc., Stony
Brook, New York, USA). Scout images along three orthogonal orientations were first acquired
for animal positioning. We used 3D Multiple Gradient Echo sequence (MGE) to acquire a
series of T2-weighted images with increasing echo time (TE) values 3.3 ms, 7.5ms, 11.4ms
and 16.0 ms. Other acquisition parameters were repetition time (TR) 34 ms, field of view
(FOV) 30 × 35 × 100 mm with a voxel size of 0.23 × 0.21 × 0.20 mm^3, 3 averages.
Longitudinal analysis of mNP tissue bio-distribution
All mice and experimental procedures were conducted using protocols approved by, and in
accordance with, the UK Home Office Animal (Scientific Procedures) Act 1986 and local eth-
ics committee at Aston University. To determine the tissue persistence of our FDG-mNPs
over a prolonged period, we injected two, 3-week-old male NMRI mice intravenously with 8
mg / kg of our FDG-mNPs in 100 μl of sterile PBS. Both mice were maintained on standard
chow and water ad libitum for either 3 or 6 months post injection. Both mice showed no visi-
ble sign of ill health, were fully mobile and increased or maintained their body weight through-
out the study. After 3 or 6 months, mice were culled via cervical dislocation. Heart, kidneys,
lungs, liver, spleen, muscle and brain tissue were fixed for 48 hours in 10% neutral buffered
formalin (Sigma, UK) at 4o C prior to storage in 70% ethanol at 4o C. Tissues were processed
into paraffin wax prior to sectioning at 5 μm. Sections from all tissues were analysed for either
for (i) gross morphology by H&E staining (by utilising standard staining protocols) or for (ii)
levels of apoptosis using the APO-BrdU TUNNEL Assay Kit (Molecular Probes, Invitrogen,
UK). The H&E stained sections were imaged using a CETI Magnum-T microscope connected
to a Jenoptik ProgRes CF camera. The APO-BrdU TUNNEL stained sections were imaged on
a Leica Microstystems DMI 4000B microscope coupled to a Leica DFC360 FX camera. Fluo-
rescent images were obtained with filters adjusted for nuclear staining with Hoechst and for
apoptotic nuclei staining with an Alexa Fluor 448 dye-labelled anti BrdU antibody. Relative tis-
sue staining intensities were measured using Volocity imaging software (Perkin Elmer, USA).
FDG-mNP in cancer
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Results
Short-term impact of FDG-mNPs
Histology results for the mice in group 1, the prostate-cancer bearing mice, are shown in Fig 2.
Corresponding MRI images for the mice in group 1 are shown in Fig 3A and 3B. FDG-mNPs
Fig 2. Growth profiles of mice injected at 3 weeks of age with 8mk/kg ICG-conjugated FDG-mNPs (A). Representative
fluorescent images of kidney (B, D) and brain (C, E) tissue sections from 3 and 6 month old mice injected with ICG-
conjugated FDG-mNPs. Tissue intensity (arbitrary units) staining for ICG-conjugated FDG-mNPs normalised to
nuclear Hoechst signal in 3 and 6 month old mice (F). n = 1 mouse per treatment group. Images in B-E are at 10x
magnification. FDG: fluorodeoxyglucose; ICG: indocyanine; mNP: magnetic nanoparticle.
https://doi.org/10.1371/journal.pone.0202482.g002
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injected intratumourally were highly concentrated in the prostate tumour compared with non-
cancerous tissues in other organs. One hour post-injection, FDG-mNP concentrations were
shown to be high in the tumour itself and the concentration appeared to be lower in the periph-
ery of the tumour compared with more centrally (although we were comparing three mice and
such differences could possibly be accounted for by individual variations amongst the mice).
Results one hour post-injection also indicated that the concentration of FDG-mNP was greatest
in the mice injected intratumourally compared with the mice injected intravenously.
Histology results for the mice in group 2, the non-cancer containing mice injected intrave-
nously and euthanised at 3 and 6 months, respectively, are shown in Fig 4. We observed no
detectable impairment in mouse well-being or behaviour in response to FDG-mNPs in these
mice 3 and 6 months post-injection.
T2-weighted gradient echo imaging and multi-echo fast spin echo imaging showed that
FDG-mNPs selectively accumulated in tumours in prostate-tumour bearing mice, as evidenced
by a reduction in T2 values and signal decrease in T2-weighted images in various areas of the
tumour mass (s 5 and 6). ROI analysis of the MRI signal change in the tumour mass showed
approximately11-fold signal reduction in mice receiving intratumoral FDG-mNPs when com-
pared against contralateral muscle background tissue (Fig 5). In addition to our observing MRI
signal reduction in the tumour mass, we also observed decreases in MRI signals in the liver and
spleen of mice injected with FDG-mNPs because of an iron oxide particle-induced T2 effect.
However, the reduction in MRI signal was lower in mice that received intravenous FDG-mNPs
compared with mice that received intratumoural FDG-mNPs ( 3% in the liver), suggesting that
Fig 3. MRI scans of tumorous hind limb of mice before and after intratumoural (A) and intravenous (B) application of FDG-mNPs. A:
The MRI scans of an animal before and after intratumoural injection of FDG-mNPs. T2-weighted gradient echo imaging and multi-
echo fast spin echo imaging on a pre-, hour 1st and 24th of injection. B: The MRI scans of an animal before and after intravenous
injection of FDG-mNPs. T2-weighted gradient echo imaging and multi-echo fast spin echo imaging on a pre-, hour 1st and 24th of
injection. FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle; MRI: magnetic resonance imaging.
https://doi.org/10.1371/journal.pone.0202482.g003
Fig 4. Representative Haemotoxylin and Eosin stained sections from mice injected with ICG-conjugated FDG-mNPs at a concentration of 8mk/kg. Sections show
representative images of brain (A), heart (B), kidney (C), liver (D), lung (E), spleen (F) and muscle (G) in a 3 month old mouse. Sections also show representative images
of brain (H), heart (I), kidney (J), liver (K), lung (L), spleen (M) and muscle (N) in a 6 month old mouse. All images are at 10x magnification. FDG: fluorodeoxyglucose;
ICG: indocyanine; mNP: magnetic nanoparticle.
https://doi.org/10.1371/journal.pone.0202482.g004
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the liver uptake of the nanoparticles was probably a normal biodistribution of FDG-mNPs (Fig
6). To further confirm the distribution of FDG-mNPs in normal and tumour tissues, Prussian
blue staining was done on tissue sections obtained from these mice that received FDG-mNPs
intravenously or intratumourally (Fig 7). Our results showed FDG-mNPs (labelled with the blue
dye) were taken up by normal cells in other organs especially in the spleen, but over time this
concentration appeared to decrease in these cells (as in the prostate tumour cells also). In mice
injected intravenously, most of the FDG-mNPs appeared to have decreased in the tissues of the
normal cells at 7 days post-injection; while the FDG-mNPs appeared to concentrate in the
spleen, these are relatively small amounts (Fig 8).
Long-term impact of FGD-mNPs
Throughout the experiment, there was no detectable impairment in mouse wellbeing. Both the
3 and 6 month mice displayed good condition of coat and no recorded weight loss for up to 6
months (Fig 2A). Tissue sections were analysed for levels of retained FDG-mNPs using fluo-
rescent microscopy (Fig 2B–2E). We observed that any detectable staining present within the
samples was not above that of background auto-fluorescence and that tissues from both the 3
and 6 month old mice displayed comparable staining intensities when compared with each
other (Fig 2F). We also conducted analyses for levels of apoptosis within all tissues samples
Fig 5. Illustration of signal intensity relative to muscle in tumour and in normal organs (liver, spleen, kidney and node) after intravenous injection of FDG-
mNPs. FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle.
https://doi.org/10.1371/journal.pone.0202482.g005
FDG-mNP in cancer
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and observed no significant or differential levels of apoptosis in any of the samples (data not
shown). Histological analysis of brain, heart, kidney, liver, lung, muscle and spleen tissues
revealed typical morphology and no overt sign of tissue damage or cellular damage (Fig 4).
Discussion
Our previous in vitro study indicated that magnetic hyperthermia, when applied to an in vitro
cell neuroblastoma cancer line injected with FDG-mNPs, could be used to destroy cancer cells
[14]. However, since a relatively large concentration of FDG-mNPs was used in that in vitro
study, it was necessary to investigate the effects of FDG-mNPs when used without magnetic
hyperthermia and when smaller concentrations are used in vivo. Our current study involved
mice with prostate cancer and normal mice, all of which were injected with a therapeutic con-
centration of FDG-mNP corresponding to that which would be used in humans (the concen-
tration was scaled for body mass and blood volume in the mice).
Our results show that FDG-mNPs do little to no damage to the tumour tissue when used
alone without magnetic heating. Moreover, further analysis in the prostate-cancer bearing
mice shows that there is relatively little FDG-mNPs remaining in the tissues of the liver, lungs
or kidneys, muscle or brain of the mice when FDG-mNPs were injected intravenously or intra-
tumourally. The highest concentration of FDG-mNPs appeared to be in the tumour of the
Fig 6. Illustration of signal intensity relative to muscle in tumour and in normal organs (liver, spleen, kidney and node) after intratumoural of FDG-mNPs.
FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle.
https://doi.org/10.1371/journal.pone.0202482.g006
FDG-mNP in cancer
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mice injected intratumourally, and this concentration decreased over time from 1 hour post-
injection to 7 days (when the mice were euthanised). It seems that in some instances the nor-
mal spleen takes up FDG-mNP (although this is still a relatively small amount compared to the
uptake by the tumour when injected intratumourally) on account of its proliferant vascularity.
However, it is also noted that the mice, both prostate-cancer bearing mice and normal mice,
appeared to be healthy in outward appearance behaviour and movement, although no formal
testing of cognitive function etc. was undertaken as part of this study. Locally, intratumorally
injected nanoparticles with concentrations ranging from a few mg ml−1 to a few hundreds of
mg ml−1 have been studied in the several in vivo experiments which are available in the litera-
ture [19]. More importantly, several studies have been shown cytotoxic analysis of iron
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particles in mice, rats and humans and demonstrating mild to tolerable side effects up to con-
centrations of 4,000 mg Fe kg−1 [20]. In a prospective phase I trial of locally recurrent prostate
cancer patients, Johannsen et al. studied the morbidity and quality of life during thermother-
apy after intraprostatic injection of iron oxide NPs. The authors showed that iron oxide NP
deposits were detectable in the prostate one year after the thermal therapy but interestingly no
systemic toxicity was observed at a median follow-up at 17.5 months. The authors concluded
that interstitial heating using magnetic nanoparticles was feasible and well tolerated in patients
with locally recurrent prostate cancer [21].
Given the results presented in this study, we feel it would be necessary to optimise the time
for a future clinical application of magnetic coil heating in relation to the time at which the
FDG-mNP is injected to minimise the heating of FDG-mNP taken up by normal tissues and
to ensure the dissipation of FDG-mNP into normal tissues.This will be the subject of further
research, involving intravenous and intratumoural applications.
We also note that there is a need for optimisation of the concentration of FDG-mNP used
in the treatment of different cancer types and this will be the subject of further research. Our
next step will involve injecting the FDG-mNPs (a) intratumourally into the prostate gland of a
mouse together with the application of magnetic hyperthemic heating to the prostate gland of
the mouse. Although the direct intratumoural injection of FDG-mNPs has obvious advantages
(e.g., with a local injection, the applied magnetic hyperthermia could likewise be targeted
locally to a given area of the body containing the cancer) the intravenous route of application
Fig 8. Histological analyses of tumour, muscle, liver and spleen after intravenous injections of FGD-mNPs after 1 hr and 7 days.
FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle.
https://doi.org/10.1371/journal.pone.0202482.g008
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also gives other potential advantages relating to treatment. In instances where cancer has
metastasized to other areas of the body, the intravenous route avails the FDG-mNPs to wider
uptake by widely distributed cancer cells. In this way, widespread cancer cells (even those too
small to be detected using current imaging techniques e.g. PET, MRI) could readily uptake the
FDG-mNPs, such that magnetic hyperthermia could then be applied whole body, thus poten-
tially leading to the destruction of these widespread metastases.
The results of the previous in vitro studies and the results of this current in vivo study pre-
sented in this paper will be used to further research of FDG-mNPs by applying hyperthermia
to mice injected with FDG-mNPs at the concentrations indicated in this current in vivo pilot
study. We note that our quantitative results regarding the uptake of FDG-mNPs by tissue
(including the prostate tumour) are based on % of iron uptake by the tissue, and that the data
obtained in this pilot study have been based on results obtained from a small number of mice.
However, we nevertheless feel that this approach concerning the uptake of FDG-mNPs in can-
cer cells (and the subsequent application of magnetic heating to the FDG-mNPs taken up by
cancer cells) is worthy of further investigation.
Conclusions
The results of our in vivo pilot study involving the uptake of FDG-mNPs by cancerous tissue
and normal tissue in mice indicate that:
➢ The FDG-mNPs are rapidly taken up (both by the intravenous route and when directly
injected into the tumour) by the cancer cells in all three groups of cancerous tissue in mice.
➢ That little FDG-mNPs are taken up by non-cancerous tissues.
➢ That over time the concentration of FDF-mNPs in both cancerous and non-cancerous tis-
sue appears to decrease over time.
➢ That there are no observable detrimental effects in the mice injected with the FDG-mNPs
over the times periods used in our study.
➢ That our results are worthy of further study, and that this technique of injecting FDG-
mNPs into cells—directly or by intravenous injection coupled with hyperthermic tech-
niques (magnetic heating coil application)—may produce an effective method of cancer cell
destruction, which could potentially have clinical applications.
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